Abstract: The invention proposes a cosmetic or pharmaceutical preparation containing a mixture of medium-chain, preferably saturated triglycerides with a fatty acid chain length of between C8 and C10 of between 60% and 98% and a content of saturated, long-chain, preferably saturated triglycerides with a fatty acid chain length of between C18 and C24 of between 2% and 40% as a vegetable replacement for Vaseline.

Abstract: A block type organopolysiloxane is represented by the following average composition formula (1), wherein each R1 independently represents a monovalent hydrocarbon group having 1 to 12 carbons; R2 represents any of a hydrogen atom, a monovalent hydrocarbon group having 1 to 15 carbons, and a monovalent acyl group having 2 to 7 carbons; R3 represents a hydrogen atom or a monovalent hydrocarbon group having 1 to 4 carbons; X represents a divalent hydrocarbon groups having 2 to 15 carbons; “n” represents an integer of 1 or more; “m” represents an integer of 1 or more; “s” represents an integer of 0 to 100; “t” represents an integer of 0 to 50; “z” represents an integer of 0 to 50; each R4 independently represents a hydrogen atom, a hydroxyl group, an alkoxy group, or an organic group represented by the general formula (2).

Abstract: A tamper-resistant pharmaceutical dosage form comprising a pharmacologically active ingredient embedded in a prolonged release matrix, which comprises a prolonged release matrix material selected from the group consisting of nonionic acrylic polymers and waxy materials and which provides prolonged release of the pharmacologically active ingredient, resistance against solvent extraction, resistance against grinding, and resistance against dose-dumping in aqueous ethanol.

Abstract: Suggested are biocide compositions, comprising (a) 2-Furoic and/or Tetrahydro-2-furoic acid amides; (b) Biocides and optionally (c) Oil components or co-solvents and/or (d) Emulsifiers. The compositions show high solubility for biocides and improved emulsification properties.

Abstract: The present invention provides an improved method of administering a medicinal, dental or nutritional agent to a non-human animal, such as a domesticated dog or cat. The method comprises mixing a liquid composition in a mixer at various speeds and pressures for a period of time; pouring the liquid composition onto a conveyor belt propelled by polymer rollers, wherein the polymer rollers allow the components to advance on the conveyor belt without adhering to the belt; evenly distributing the composition on the belt with the use of a knife; heating the composition in one or more hot-air chambers; obtaining a film comprised of the composition; cutting the film into strips; and then administering one or more of the strips to the non-human animal by placing the strip under the tongue of the animal, i.e., by sub-lingual administration.

Abstract: A pharmaceutical composition comprising a pharmaceutically effective amount of a pharmaceutically active substance and a pharmaceutically acceptable carrier including a cationic excipient, wherein said cationic excipient is a labile ester of betaine and a lipophilic alcohol having at least one primary hydroxyl group. Also, the use of a labile ester of betaine and a lipophilic alcohol having at least a primary hydroxyl group as a cationic excipient in a carrier for a pharmaceutical composition comprising a pharmaceutically active substance.

Abstract: The present invention relates to a pharmaceutical composition comprising glycerol esters of a fatty acid, wherein the compositions are useful for the delivery of anti-psychotic drugs.

Abstract: The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.

Abstract: Described herein are cyclodextrin-stabilized microemulsion systems useful for increasing the solubility, stability, bioavailability, or safety of an active agent for delivery to the skin. The microemulsions may reduce the occurrence of skin irritation or odor upon application. In certain embodiments, the active agent is substantially insoluble in water. The microemulsions may be formulated as semi-solids, for example creams, or as aerosol or non-aerosol foams. Also described are methods of treating skin disorders, comprising the step of applying to an affected area of a subject in need thereof a therapeutically-effective amount of an inventive microemulsion.

Abstract: Tankmix additive concentrates containing a phosphate ester and/or polymeric surfactant and a triglyceride fatty acid ester and the use of aqueous herbicide spray mixtures incorporating such tankmix additive concentrates are described. The tankmix additive concentrates described herein include from 1 to 50 weight percent of a phosphate ester surfactant, a polymeric surfactant, or mixtures thereof, and from 1 to 90 weight percent of a triglyceride fatty acid ester. The tankmix additive concentrates form a stable emulsion upon dilution into a pesticide spray mixture.

Abstract: The present invention relates to compositions containing a) at least one monoacyl lipid; b) at least one diacyl glycerol and/or tochopherol; and c) at least one fragmentation agent; and optionally an active agent. The compositions are capable of self-dispersing to provide colloidal non-lamellar particles upon contact with an aqueous fluid. The invention additionally provides a method for forming non-lamellar particles from such compositions, and pharmaceutical formulations containing the compositions, plus non-lamellar particles formable from the compositions.

Abstract: Composition containing quaternary ammonium compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, the composition including at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 16 carbon atoms. Ophthalmic oil-in-water emulsions containing such compositions, the ophthalmic emulsions being useful for eye care or for the treatment of eye conditions are also disclosed.

Abstract: Methods for enhancing the release and/or absorption of poorly water soluble active agents are described herein. The method involves dissolving, melting, or suspending a poorly water soluble active agent in one or more molten fatty acids, conjugated fatty acids, (semi-) solid surfactants of high HLB value, and/or hydrophilic polymers. The molten active agent mixture is then suspended and homogenized in a hydrophilic or lipophilic carrier to form microparticles suspended in the hydrophilic or lipophilic carrier. The particles suspended in the hydrophilic or lipophilic carrier can be encapsulated in a hard or soft gelatin or non-gelatin capsule. It is believed that the microparticles produced by the method described above will exhibit enhanced dissolution profiles. In vitro release studies of formulations containing cilostazol and fenofibrate showed 100% dissolution of cilostazol in 15 minutes and over 90% dissolution of fenofibrate in 35 minutes.

Abstract: Disclosed herein is preferably a multi-dose type non-aqueous oily injectable formulation including; an active ingredient (drug) expressing therapeutic effects, which is dissolved, dispersed or suspended in a therapeutically effective amount, in oil. The disclosed non-aqueous oily injectable formulation may include; an oil-affinitive preservative, and a hydrophilic excipient non-phase separable from the oil-affinitive preservative when the excipient is mixed with the oil-affinitive preservative.

Abstract: Provided is a percutaneous absorption type formulation of a drug such as imidafenacin and silodosin, wherein stable absorption through the skin is realized. The percutaneous absorption type formulation containing a drug such as imidafenacin and silodosin further contains a transdermal absorption promoting agent, and fatty acid ester and/or fatty acid amide that further improve(s) the function of the transdermal absorption promoting agent.

Abstract: The invention relates to stable oleaginous cosmetic or therapeutic foam compositions containing certain active agents, having unique therapeutic properties and methods of treatment using such compositions. The foamable composition includes at least one solvent selected from a hydrophobic solvent, a silicone oil, an emollient, a co-solvent, and mixtures thereof, wherein the solvent is present at a concentration of about 70% to about 96.5% by weight of the total composition, at least a non-ionic surface-active agent at a concentration of about 0.1% to less than about 10% by weight of the total composition; at least one gelling agent at a concentration of about 0.1% to about 5% by weight of the total composition; a therapeutically effective amount of at least one active agent; and at least one liquefied or compressed gas propellant, at a concentration of about 3% to about 25% by weight of the total composition.

Abstract: O/W-emulsifiers are described, comprising: (a) 30-50% by weight of hardened palm oil glycerides; (b) 15-35% by weight of potassium cetyl phosphates; (c) 20-30% by weight of cetyl alcohol, and (d) 5-15% by weight of potassium phosphate, in each case with respect to the total mass of the emulsifier. Further described are corresponding O/W-emulsions, comprising an aqueous phase, an oil phase dispersed in the aqueous phase and between 0.25 and 15% by weight of the abovementioned O/W-emulsifier. Finally, also described are methods for manufacturing such an O/W-emulsion.

Abstract: A liquid composition of an insoluble medicament and a preparation method thereof are disclosed. The composition includes insoluble medicament, oil for injection, phospholipid, and solvent; the percentage by weight of each component is as follows: insoluble medicament 0.01-10%, oil for injection 0%-20%, phospholipid 10-80%, solvent 20-89%. The preparation method for the composition includes the following steps: dissolving an insoluble medicament into solvent or oil for injection or a mixture thereof firstly, and then adding other components, and mixing uniformly; or dissolving an insoluble medicament into a mixture of other components, and mixing uniformly; or dissolving an insoluble medicament into part of solvent firstly, and then adding into a mixed solvent of other components and the remaining solvent, and mixing uniformly.

Abstract: O/W-emulsifiers are described, comprising: (a) 30-50% by weight of hardened palm oil glycerides; (b) 15-35% by weight of potassium cetyl phosphates; (c) 20-30% by weight of cetyl alcohol, and (d) 5-15% by weight of potassium phosphate, in each case with respect to the total mass of the emulsifier. Further described are corresponding O/W-emulsions, comprising an aqueous phase, an oil phase dispersed in the aqueous phase and between 0.25 and 15% by weight of the abovementioned O/W-emulsifier. Finally, also described are methods for manufacturing such an O/W-emulsion.

Abstract: Methods and compositions for the production of food compositions, oils, fuels, oleochemicals, and other compounds in recombinant microorganisms are provided, including oil-bearing microorganisms and methods of low cost cultivation of such microorganisms. Microalgal cells containing exogenous genes encoding, for example, a lipase, a sucrose transporter, a sucrose invertase, a fructokinase, a polysaccharide-degrading enzyme, a keto acyl-ACP synthase enzyme, a fatty acyl-ACP thioesterase, a fatty acyl-CoA/aldehyde reductase, a fatty acyl-CoA reductase, a fatty aldehyde reductase, a fatty aldehyde decarbonylase, and/or an acyl carrier protein are useful in manufacturing food compositions, and transportation fuels such as renewable diesel, biodiesel, and renewable jet fuel, as well as oleochemicals such as functional fluids, surfactants, soaps and lubricants.

Abstract: Particles having a tap density of less than 0.4 g/cm3 include a hydrophobic amino acid or salt thereof and a therapeutic, prophylactic or diagnostic agent or any combination thereof. Preferred particles include a phospholipid, have a median geometric diameter between about 5 and about 30 microns and an aerodynamic diameter between about 1 and about 5 microns. The particles can be formed by spray-drying and are useful for delivery to the pulmonary system.

Abstract: The invention relates to polyol partial esters, cosmetic and pharmaceutical formulations containing the polyol partial esters according to the invention, and to the use of the polyol partial esters according to the invention for cosmetic and pharmaceutical purposes.

Abstract: The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.

Abstract: A liquid composition in an osmotic drug delivery system and a dosage form in an osmotic drug delivery system is disclosed comprising an amphiphilic molecule, a non-aqueous liquid solvent, and a pharmaceutically active agent.

Abstract: The invention relates to an additive comprising at least 95 wt. % of a mixture consisting of at least one organic filter filtering UVA, at least one organic filter filtering UVB, and from 1 to 50 wt. % of at least one non-volatile oil that is a solvent for said filters. This composition is particularly useful as an agent for protecting the organoleptic properties of a transparent cosmetic composition, against UV radiation.

Abstract: A cosmetic raw material comprising the following components (A), (B), and (C): (A) a specific polyether-modified organopolysiloxane; (B) a chain-form silicone oil that is a liquid at 25° C., does not contain a cyclic structure, and does not contain a resinous structure; and (C) an oil that is a liquid at 30° C. and that characteristically (c1) has at least one hydroxyl group in each molecule, (c2) has from 0 to 3, as the number of moles of addition, oxyethylene units in each molecule, (c3) has an HLB value in the range from 0.1 to 6.0, and (c4) has an average molecular weight in the range from 200 to 7000.

Abstract: Reverse hexagonal mesophase (HII) liquid crystals are provided and relating therapeutic and non-therapeutic applications are demonstrated.

Abstract: A lipid particle can include a plurality of cationic lipids, such as a first cationic lipid and a second cationic lipid. The first cationic lipid can be selected on the basis of a first property and the second cationic can be selected on the basis of a second property. The first and second properties are complementary. The attributes of the lipid particle can reflect the selected properties of the cationic lipids, and the complementary nature of those properties.

Abstract: The present invention relates to an oil-in-water (O/W) type nano-emulsion composition comprising an oil component containing oil and a polyethylene glycol ester-based emulsifier; and a water component containing a polyol or a polyol derivative. The present invention also relates to a cosmetic composition comprising the oil-in-water type nano-emulsion composition, and to a method for preparing the oil-in-water type nano-emulsion composition. According to the present invention, a nano-sized low-viscosity emulsion having a high inner phase can be obtained through the method that is different from the conventional methods of phase inversion temperature emulsification or high pressure emulsification, thereby significantly improving the stability of the emulsion. In addition, the nano-emulsion composition of the present invention can be added to a variety of cosmetic compositions having a variety of methods of use and can thus deliver active ingredients to the skin effectively since it has small-sized particles.

Abstract: The invention relates to a foam formulation comprising an emulsion, comprising an oil phase and an aqueous phase, wherein the emulsion comprises at least one triterpenoid. Further the invention relates to anemulsion comprising an oil phase and an aqueous phase, wherein the emulsion comprises at least one triterpenoid selected from the group consisting of betulin, betulinic acid, lupeol, erythrodiol, oleanolic acid, (C1-C6) alkyl esters of the aforementioned acids, or mixtures thereof, and wherein the oil phase comprises at least one membrane-forming substance forming a lamellar arranged membrane in the emulsion.

Abstract: The present invention is directed to compositions and methods of preparation of phospholipid depots that are injectable through a fine needle.

Abstract: A transdermal therapeutic system for administering lipophilic, poorly water-soluble and/or sparingly skin-permeable pharmaceutical active substances. The active substance is present in a multi-component enhancer system consisting of 4 components and each component of the multi-component enhancer system is selected from a different one of the substance groups: a) terpenes, b) cyclic glucitol ethers, c) medium-chain triglycerides of capric and caprylic acid and/or of linoleic acid; and d) longer-chain alcohols having a chain length of 8 or more carbon atoms.

Abstract: The present invention relates to a novel liquid delivery carrier comprising a specific grade of glyceryl caprylate and PEG-40 hydrogenated castor oil in particular amounts. This carrier can be loaded with slightly or poorly water soluble substances and filled into hard gelatin capsule shells for final administration to a subject. Also disclosed are filling compositions comprising such delivery carrier and hard gelatin capsules filled with the carrier and the composition of the invention. The delivery carrier of the invention proved to be compatible with both the hard gelatin capsule shells and the substances loaded into it.

Abstract: The present invention relates to cosmetic compositions containing polyglycerol partial esters of linear, unsubstituted carboxylic acids with the provisos that the polyglycerol obtained by hydrolysis or alcoholysis of the polyglycerol partial ester comprises an average degree of polymerization of from 2 to 8 and the polydispersity index of said polyglycerol is greater than 0.75. The present invention also relates to the use of aforementioned polyglycerol esters for the production of and use in cosmetic compositions.

Abstract: Novel acoustically sensitive drug carrying particles comprising low concentrations of phosphatidylethanolamine are disclosed, as well as uses and methods thereof. The drug carrying particles accumulate in the diseased target tissue and efficiently release their payload upon exposure to acoustic energy.

Abstract: The present invention relates to a carrier composition comprising a phosphate compound of an electron transfer agent and a polar aprotic solvent. Biologically active compounds formulated with the carrier composition have been shown to have improved properties.

Abstract: The present invention relates to compositions and methods for liquid statin products suitable for use in a person or animal. The invention provides stable liquid formulations containing a statin and at least one solubilizer. Methods for the oral administration of statin formulations are also provided by the invention.

Abstract: The invention is directed to a barrier composition, to a vehicle comprising said barrier composition, to a layer comprising said barrier composition, to a foodstuff comprising said vehicle or layer, to a pharmaceutical or nutraceutical composition comprising said vehicle or layer, to a method for protecting one or more active ingredients, and to the use of said barrier composition. The barrier composition of the invention comprises: a hydrophobic organic phase; and 0.1-75 vol. %, based on the total volume of the barrier composition, of biodegradable solid plate-like particles.

Abstract: Stable formulations for the oral administration of therapeutic agents, methods for administering therapeutic agents using the formulations, and methods for treating conditions and diseases using the formulations.

Abstract: A pharmaceutical composition for external use which is an organogel containing a fatty acid ester and a glycerolglycerin fatty acid ester, in particular, a novel transdermally absorbable pharmaceutical composition for external use which has a drug such as non-narcotic analgesics as an active ingredient made in organogel form containing a drug such as non-narcotic analgesics as an active ingredient, a fatty acid ester and a glycerolglycerin fatty acid ester, and a method for producing the composition. The pharmaceutical composition significantly improves skin permeability of drugs such as non-narcotic analgesics and allows a sufficient amount of drug to permeate the skin sustainably. Moreover, since the pharmaceutical composition is in organogel form, it can be easily applied to a preparation in practice. In addition, the pharmaceutical composition can provide efficient use and the like of drugs due to a high drug release rate and therefore is highly useful.

Abstract: A stable soft gel dosage form for acetylsalicylic acid (ASA), aspirin, is provided wherein soft gel capsules containing the ASA can be stored for prolonged periods under typical home storage conditions with better than 98% or 99% ASA integrity and with negligible physical or chemical deterioration of the soft gelatin capsule over the period of six months. A suspension of ASA in a monoglyceride component comprising more than about 50% glyceryl monooleate is packaged in a soft gelatin capsule, which can be substantially free of other components. The ASA in this composition is resistant to hydrolysis from water contained within the soft gelatin matrix or diffusing through the matrix. Methods of preparation and methods of use are also provided.

Abstract: The present invention relates to a stable liquid formulation comprising desoximetasone, isopropyl myristate, a C2-C4 alcohol and a stabilizing agent. Specifically, the present invention provides a liquid formulation comprising: a) about 0.01 wt % to about 2.5 wt % desoximetasone; b) about 10 wt % to about 70 wt % isopropyl myristate; c) about 20 wt % to about 70 wt % C2-C4 alcohol; and d) a stabilizing agent selected from the group consisting of an oleaginous vehicle and a propellant, wherein the stabilizing agent is in an amount sufficient to reduce the formation of less than about 1 wt % 17-carboxy-9?-fluoro-11?-hydroxy-16a-methyl-androsta-1,4-diene-3-one under an accelerated storage condition.

Abstract: The present invention relates to a method for preparing an oral lyophilizate composition comprising: a) forming a liquid phase by using at least one homogenising agent having tensioactive properties, said liquid phase comprising at least an active pharmaceutical ingredient, a filler and/or a binding agent and a solvent, b) lyophilizing said liquid phase to form the oral lyophilizate composition.

Abstract: (PEG)-lipid conjugates and methods of preparation are disclosed herein. Methods of preparation may involve stepwise addition of small PEG oligomers to a glycerol backbone until a desired chain size is attained. Polymers resulting from the syntheses may be highly monodisperse. The resulting polymers may comprise branched polyethyleneglycol (PEG)-lipid conjugates. The present disclosure may provide several advantages such as simplified synthesis, high product yield and low cost for starting materials. The present synthesis method may be suitable for preparing a wide range of conjugates such as PEG lipid conjugates having a glycerol-like central backbone covalently attached to two or more monodisperse PEG chains and a lipid comprising a range of diesters made from fatty acids or bile acids.

Abstract: Described are compositions, containing a. compounds selected from (i.) hydrogenated and/or non-hydrogenated, ethoxylated and/or propoxylated triglycerides of ricinoleic acid having degree of ethoxylation and/or propoxylation of ?20, (ii.) addition products of 2-50 mol ethylene oxide on sorbitan monoesters and/or diesters of saturated or unsaturated fatty acids having 6-22 carbon atoms, and (iii.) addition products of 2-50 mol ethylene oxide and 1-20 mol propylene oxide on alpha olefin epoxides having 8-22 carbon atoms and ring-opened with polyols, b. ethoxylated and/or propoxylated glycerol fatty acid monoester and/or diester having degree of ethoxylation of ?20, c. polyol selected from glycerol, diglycerol, trigylcerol, tetraglycerol, alkylene glycols and polyalkylene glycols, d. glycerol fatty acid monoester of the general formula (I), where R1 is saturated or unsaturated, branched or linear group having 9-19 carbon atoms, and e. ?20 wt % water.

Abstract: A lipid layer forming wound healing promoting composition comprising volatile silicone oil, polar lipid, C2-C4 aliphatic alcohol, and a wound healing agent, in particular a low to medium size natural or synthetic peptide. Also disclosed is a method of forming the lipid layer on a wound and a medical patch provided with the composition.

Abstract: There are provided various compounds and compositions comprising polyunsaturated fatty acid monoglycerides and derivatives thereof. These compounds and compositions can be useful as cancer chemopreventive agents. They can also be useful for enhancing solubility of various active agents and enhancing their bioavailability.

Abstract: An ophthalmic solution comprising a polyethoxylated glyceride in the range of 0.001 to about 10 percent by weight and a buffer agent. These solutions impart surprising comfort and wearability to contact lenses. At the same time the solutions provide good preservative capacity and do not increase protein deposit.

Abstract: The present invention relates to preservation of cosmetic formulations. More specifically, the present invention relates to a preservative composition for cosmetic formulations comprising thymol, monolaurin and magnolol obtained from supercritical fluid extracts of Magnolia officinalis.

Abstract: Novel acoustically sensitive drug carrying particles comprising non-lamellar forming lipids are disclosed, as well as uses and methods thereof. The drug carrying particles accumulate in the diseased target tissue and efficiently release their payload upon exposure to acoustic energy.